A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)

NCT05548621 · tracked via the Priya Life Science Netherlands tracker

Sponsor

St. Antonius Hospital

Phase

Observational

Started

2022-11-24

Last updated

2025-05-15

Condition(s) studied

Renal Cell CarcinomaRenal Cell Carcinoma Metastatic

Investigational drug(s) / intervention(s)

Decision aid

Decision aid: Online interactive decision aid for RCC

Study summary

The aim of this study is to evaluate the effect of two decision aids for renal cell carcinoma (RCC) on the decision-making process and the quality of the decision.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients clinically diagnosed with RCC * Patients facing a decision which is addressed in the decision aids (T1 tumor or metastatic disease) * Written informed consent Exclusion Criteria: * Patients who are not able to fill in a questionnaire or undergo an interview individually

Primary outcome measure(s)

OPTION-5 — During consultation
Observed patient involvement in decision-making

Trial sites (1)

Facility	City	Region	Status
St. Antonius Ziekenhuis	Nieuwegein	Utrecht	Recruiting

More St. Antonius Hospital trials in the Netherlands

Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer Recruiting

Biomarkers in Perioperative Management Recruiting

The Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI) Recruiting

Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device Recruiting

Online Medical Hypnosis Exercises to Improve Mental Health in Primary School Children and Prevent Future Mental Health Issues Recruiting

Other trials for the same condition

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting

Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer Active, not recruiting

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma Active, not recruiting

National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05548621 on ClinicalTrials.gov ↗ ← All trials in the Netherlands